SCHEMBL25758323

SCHEMBL25758323

CCCCOc1ccc(S(=O)(=O)N2CCC(CCc3ccccc3)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.60
TSHR P16473 1/20 0.60
MAPK1 P28482 1/20 0.60
RECQL P46063 1/20 0.60
KMT2A Q03164 6/20 0.57
MEN1 O00255 4/20 0.57
KCNH2 Q12809 1/20 0.51
ALDH1A1 P00352 2/20 0.48
GAA P10253 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CHRM5 P08912 1/20 0.48
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27487981 0.79 ALDH1A1 (0.67) L3MBTL1TSHRMAPK1RECQLKMT2A
SCHEMBL6980419 0.78 KMT2A (0.55) L3MBTL1TSHRMAPK1RECQLKMT2A
SCHEMBL4283386 0.78 L3MBTL1 (0.61) L3MBTL1TSHRMAPK1RECQLKMT2A
SCHEMBL6983340 0.75 ADRB3 (0.59) L3MBTL1TSHRMAPK1RECQLKMT2A
SCHEMBL6986391 0.75 TSHR (0.64) L3MBTL1TSHRMAPK1RECQLKMT2A
SCHEMBL22032920 0.74 DHCR7 (0.67) L3MBTL1TSHRMAPK1RECQLKMT2A
SCHEMBL6982332 0.74 L3MBTL1 (0.74) L3MBTL1TSHRMAPK1RECQLKMT2A
SCHEMBL7511982 0.74 TSHR (0.62) L3MBTL1TSHRMAPK1RECQLKMT2A
SCHEMBL31454320 0.73 MCOLN3 (0.66) TSHRKMT2AMEN1ALDH1A1PKM
SCHEMBL10900503 0.73 KMT2A (0.48) L3MBTL1TSHRMAPK1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157124-A Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2023-05-23 CN claimed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
CN-116157124-A Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2023-05-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 L3MBTL1 4546/4885TSHR 2366/4885MAPK1 3942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.